9637 — Alebund Pharmaceuticals (Jiangsu) Income Statement
0.000.00%
Last trade - 00:00- HK$6.09bn
- HK$5.13bn
- CNY30.56m
Annual income statement for Alebund Pharmaceuticals (Jiangsu), fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 6.53 | 30.6 |
| Cost of Revenue | ||
| Gross Profit | 2.38 | 13.4 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Operating Interest Expense / Income | ||
| Unusual Expense / Income | ||
| Other Operating Expenses | ||
| Total Operating Expenses | 312 | 669 |
| Operating Profit | -306 | -638 |
| Total Net Non Operating Interest Income / Expense | ||
| Total Net Non Operating Interest Income / Expense | ||
| Net Income Before Taxes | -335 | -752 |
| Provision for Income Taxes | ||
| Net Income After Taxes | -335 | -752 |
| Minority Interest | ||
| Net Income Before Extraordinary Items | ||
| Net Income | -326 | -750 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -326 | -750 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -0.959 | -2.15 |